Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Guoqin Su"'
Autor:
Olorunfemi A. Oshagbemi, Pedro Lopez-Romero, Cornelis Winnips, Katalin R. Csermak, Guoqin Su, Elodie Aubrun
Publikováno v:
Malaria Journal, Vol 22, Iss 1, Pp 1-7 (2023)
Abstract Background Children in sub-Saharan Africa (SSA) remain the most vulnerable to malaria and malaria mortality. This study estimated the disease burden and distribution of Plasmodium falciparum malaria among children with age categories (0 to
Externí odkaz:
https://doaj.org/article/359ee32a7010422b8b90dbbd333fb0f8
Autor:
Vito Baraka, Abel Nhama, Pedro Aide, Quique Bassat, Agatha David, Samwel Gesase, Jonathan Gwasupika, Sebastian Hachizovu, Geofrey Makenga, Christian Ruchaho Ntizimira, Orikomaba Obunge, Kitoto Antoinette Tshefu, Marc Cousin, Nekoye Otsyula, Rashidkhan Pathan, Céline Risterucci, Guoqin Su, Christine Manyando
Publikováno v:
Malaria Journal, Vol 22, Iss 1, Pp 1-11 (2023)
Abstract Background This study aimed to evaluate the gap between guidelines and local clinical practice for diagnosis and treatment of uncomplicated and severe malaria, the patient characteristics, diagnostic approach, treatment, and compliance to st
Externí odkaz:
https://doaj.org/article/f8c57da348e04d94811c5f69c0a69b8b
Autor:
Gilles Ndayisaba, Adoke Yeka, Kwaku Poku Asante, Martin P. Grobusch, Etienne Karita, Henry Mugerwa, Stephen Asiimwe, Abraham Oduro, Bakary Fofana, Seydou Doumbia, Jay Prakash Jain, Sarita Barsainya, Gerd A. Kullak-Ublick, Guoqin Su, Esther K. Schmitt, Katalin Csermak, Preetam Gandhi, David Hughes
Publikováno v:
Malaria Journal, Vol 20, Iss 1, Pp 1-10 (2021)
Abstract Background The novel anti-malarial cipargamin (KAE609) has potent, rapid activity against Plasmodium falciparum. Transient asymptomatic liver function test elevations were previously observed in cipargamin-treated subjects in two trials: one
Externí odkaz:
https://doaj.org/article/890ef9801b434e61bb32253a0c40d2ec
Publikováno v:
Therapeutic Advances in Endocrinology and Metabolism, Vol 6 (2015)
Objective: Bisphosphonates are the most effective therapeutic agents in patients with Paget’s disease of bone. As a result of their inhibition of osteoclastic activity, hypocalcemia of variable frequency and severity following intravenous bisphosph
Externí odkaz:
https://doaj.org/article/a912212faf3d4c18a488ffd8686b5aa7
Autor:
Adoke Yeka, Judith Straimer, Guoqin Su, Martin P. Grobusch, Kwaku Poku Asante, Vinay Kumar Venishetty, Sarfaraz Sayyed, Stephen Asiimwe, Gilles F. Ndayisaba, Sarita Barsainya, Abraham Oduro, Caroline Boulton, Henry Mugerwa, Esther K. Schmitt, Etienne Karita, Katalin Csermak Renner, Seydou Doumbia, P. Gandhi, Ivan Demin, Bakary Fofana
Publikováno v:
Clinical infectious diseases. Oxford University Press
Background Cipargamin (KAE609) is a potent antimalarial in a phase II trial. Here we report efficacy, pharmacokinetics, and resistance marker analysis across a range of cipargamin doses. These were secondary endpoints from a study primarily conducted
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::976d24df7b3925eb85fe952adea3a862
https://pubmed.ncbi.nlm.nih.gov/34410358
https://pubmed.ncbi.nlm.nih.gov/34410358
Publikováno v:
Statistical methods in medical research. 28(12)
In the clinical development of some new infectious disease drugs, early clinical pharmacology trials may predict with high confidence that the efficacious doses are well below the range of the safety margin. In this case, a dose-ranging study may be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7cf8ac7be701710dc81afa65d3915cd
https://pubmed.ncbi.nlm.nih.gov/30375280
https://pubmed.ncbi.nlm.nih.gov/30375280
Autor:
Trisha F. Hue, Christina Bucci-Rechtweg, R. Eastell, Dennis M. Black, Steven Boonen, Guoqin Su, Peter Mesenbrink, Ian R. Reid, Kenneth W. Lyles
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 98:557-563
Annual infusions of zoledronic acid 5 mg over 3 years have been shown to reduce fracture incidence. There is now evidence that the effects of a single dose of zoledronic acid on bone mineral density and bone turnover last for much more than a year. W
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d646657a81cebd036e034619d3612e15
https://doi.org/10.1210/jc.2012-2868
https://doi.org/10.1210/jc.2012-2868
Autor:
A. S. Hedayat, Guoqin Su
Publikováno v:
The American Statistician. 66:25-33
The robust properties of the simultaneous estimators of location and scale parameters (μ*, σ*) proposed by Brown and Hwang are studied. As a pair of simultaneous M estimators of location and scale, their asymptotic efficiencies (0.650 for μ* and 0
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::36fee7f831c4e17471ee719a0fdb2b8b
https://doi.org/10.1080/00031305.2012.663665
https://doi.org/10.1080/00031305.2012.663665
Autor:
Felicia Cosman, Jane A. Cauley, Guoqin Su, Z. Man, Christina Bucci-Rechtweg, Kurt Lippuner, Ping-Chung Leung, Steven R. Cummings, Ruvie Lou Maria Martinez, Ian R. Reid, Monique Tan, Steven Boonen, Trisha F. Hue, Dennis M. Black, Mary Ellen Ruzycky, Richard Eastell, Peter L. Lakatos
Publikováno v:
Journal of Bone and Mineral Research. 27:243-254
Zoledronic acid 5 mg (ZOL) annually for 3 years reduces fracture risk in postmenopausal women with osteoporosis. To investigate long-term effects of ZOL on bone mineral density (BMD) and fracture risk, the Health Outcomes and Reduced Incidence with Z
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca5e9c77108542abfa559b2ce21ae649
https://doi.org/10.1002/jbmr.1494
https://doi.org/10.1002/jbmr.1494
Autor:
An Sermon, Guoqin Su, Kenneth W. Lyles, Cathleen S. Colón-Emeric, Patrick Haentjens, Jean-Marc Kaufman, Christina Bucci-Rechtweg, Frank Claessens, Koen Milisen, Jay Magaziner, Richard Witvrouw, Dirk Vanderschueren, Steven Boonen, Jonathan D. Adachi, Eric S. Orwoll, René Rizzoli
Publikováno v:
Journal of the American Geriatrics Society, Vol. 59, No 11 (2011) pp. 2084-2090
OBJECTIVES: To assess the efficacy of once-yearly zoledronic acid (ZOL) 5 mg in increasing bone mineral density (BMD) in men with a recent hip fracture participating in the Health Outcomes and Reduced Incidence with Zoledronic Acid Once-Yearly Recurr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::687f4863052ae34742b7de0224f628b3
https://doi.org/10.1111/j.1532-5415.2011.03666.x
https://doi.org/10.1111/j.1532-5415.2011.03666.x